Follow-up
cSCC, cSCC lesions, death
ADVERSE EVENTS, GRAFT LOSS, SKIN LESIONS
After conversion to sirolimus, all patients had appointments with a nephrologist with laboratory evaluations in a weekly basis in the first month, biweekly in the second month, monthly between the third and twelfth month, and every 3 months from one year to three years. Patients were evaluated by two dedicated dermatologists at baseline (T0), and at 12 (T1), 24 (T2), and 36 (T3) months. At each visit, a complete physical examination looking for skin lesions was performed, and all the new-suspected lesions were biopsied. The following information was registered: number of new biopsy-proven cSCC lesions; number of cSCC in scalp, face and neck; number of cSCC moderately differentiated; number of cSCC poorly differentiated; number of cSCC with perineural invasion.The efficacy was evaluated comparing the incidence densities off all the confirmed cSCC observed at each study visit during three years of follow up in the SRL versus the CNI groups. Moreover, we also compared the incidence densities of confirmed cSCC stratified by each high-risk criterion. The safety of the strategy was evaluated by the time course of kidney function, the incidence rates of biopsy-proven acute rejection, and the occurrence of graft loss and recipients’ death. In the SRL group, the occurrence of adverse events, the rates and causes of SRL discontinuation and the development of 